Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. RCKT
10. IBM

Go back to Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat

Novavax Reports First Quarter 2020 Financial Results

May 11, 2020 4:05 PM EDT

CEPI increases investment up to $388 million for NVXCoV2373 vaccine development & manufacturingNVXCoV2373 Phase I trial initiating in May with preliminary results in JulyNanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trialCompany to host conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2020.

... More